Polaryx Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLYX research report →
Range $6 – $7
Price Chart
About the company
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL.
- CEO
- Alex Yang
- IPO
- 2026
- Employees
- 11
- HQ
- Paramus, NJ, US
Get TickerSpark's AI analysis on PLYX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $66.30M
- P/E
- -7.35
- Fwd P/E
- 6.82
- PEG
- 0.08
- P/S
- 0.00
- P/B
- 8.71
- EV/EBITDA
- -6.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -136.66%
- ROIC
- -99.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,821,000
- Net Income
- $-8,985,000+70.4%
- EPS
- $-0.19-18.8%
- OCF Growth
- -53.3%
- FCF Growth
- -53.3%
- 52W High
- $48.91
- 52W Low
- $1.30
- 50D MA
- $1.92
- 200D MA
- $3.10
- Beta
- -8.28
- RSI (14)
- 26
- Avg Volume
- 36.42K
No earnings-call transcripts are available for PLYX yet.
- Free Float
- 46.5%
- Shares Outstanding
- 49.85M
- Float Shares
- 23.17M
of shares held by institutions
13 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1.66M | ▼ 2.04K |
| Geode Capital Management, LLC | 138.76K | ▼ 32.24K |
| Vanguard Fiduciary Trust Co | 80.32K | ▼ 24.75K |
| State Street Corp | 68.00K | ▲ 9.90K |
| Blackrock, Inc. | 41.01K | 0 |
| Hrt Financial LP | 33.10K | ▼ 48.99K |
| Northern Trust Corp | 27.99K | 0 |
| Cerity Partners LLC | 10.43K | ▲ 10.43K |
| Allworth Financial LP | 7.73K | 0 |
| Vanguard Global Advisers, LLC | 6.32K | 0 |
| Ubs Group AG | 4.36K | ▲ 3.07K |
| Tower Research Capital LLC (Trc) | 1.85K | ▼ 1.15K |
Held by 25 ETFs
Biggest fund positions in PLYX by dollar value.
Our PLYX coverage
Recent articles, reports, and earnings notes.
No research on PLYX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLYX report →Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event
globenewswire.com · Nov 20
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
globenewswire.com · Nov 9
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
globenewswire.com · Sep 1
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
globenewswire.com · Aug 25
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
globenewswire.com · May 28
Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards
globenewswire.com · May 14
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
globenewswire.com · Apr 23
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
globenewswire.com · Apr 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.